Regeneron Pharmaceuticals, Inc. (REGN)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Regeneron Pharmaceuticals, Inc. (REGN) trades at $654.27 with AI Score 90/100 (Grade A+). Regeneron Pharmaceuticals, Inc. is a leading biotechnology company focused on discovering and developing innovative medicines for various diseases. Market cap: $67.40B, Sector: Healthcare.
Price live · AI analysis from May 10, 2026REGN stock analysis for 2026: Analysts have set a consensus price target of $854.53 for Regeneron Pharmaceuticals, Inc., suggesting 30.6% upside from the current price of $654.27. The AI MoonshotScore is 90/100, indicating a strong bullish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
REGN: 5/7 perspectives are bullish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Regeneron Pharmaceuticals, Inc. (REGN) Healthcare & Pipeline Overview
Regeneron Pharmaceuticals, Inc. stands out in the biotechnology sector with its innovative drug portfolio, including treatments for eye diseases and asthma, and a strong commitment to research and development, positioning itself as a key player in addressing unmet medical needs globally.
What Is the Investment Thesis for REGN?
Regeneron Pharmaceuticals, Inc. presents a compelling investment thesis driven by its robust product portfolio and strong financial metrics. With a market capitalization of $67.40B and a P/E ratio of 14.3, the company demonstrates solid profitability, evidenced by a profit margin of 29.6% and a gross margin of 84.5%. The ongoing success of EYLEA and Dupixent, along with new product launches and an extensive pipeline, are expected to drive revenue growth in the coming years. Additionally, Regeneron's strategic collaborations with industry leaders provide opportunities for expanding its market reach and enhancing its research capabilities. However, potential risks include regulatory hurdles and competition from generic drugs, which could impact future earnings. Overall, Regeneron’s commitment to innovation and its strong financial position make it a noteworthy player in the biotechnology sector.
Based on FMP financials and quantitative analysis
REGN Key Highlights
- Market capitalization of $67.40B reflects strong investor confidence and market position.
- P/E ratio of 14.3 indicates a favorable valuation compared to industry peers.
- Profit margin of 29.6% showcases operational efficiency and effective cost management.
- Gross margin of 84.5% highlights the high profitability of its product offerings.
- Beta of 0.40 suggests lower volatility compared to the broader market, appealing to risk-averse investors.
Who Are REGN's Competitors?
REGN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ELV Elevance Health Inc. | $417.89 | +0.41% | $90.75B | 86 |
| CI Cigna Corporation | $287.77 | +3.86% | $76.12B | 79 |
| COR Cencora, Inc. | $296.51 | +2.80% | $57.69B | 74 |
| ZTS Zoetis Inc. | $74.80 | +3.24% | $31.36B | 84 |
| ARGX argenx SE | $939.68 | +3.32% | $58.15B | 49 |
| ANAB AnaptysBio, Inc. | $63.42 | -3.07% | $2.73B | 79 |
| SNDX Syndax Pharmaceuticals, Inc. | $21.82 | +4.45% | $1.93B | 79 |
| CGEN Compugen Ltd. | $2.28 | +7.04% | $215.58M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are REGN's Key Strengths?
- Strong product portfolio with established market leaders like EYLEA and Dupixent.
- High gross margins indicating operational efficiency.
- Robust pipeline of innovative therapies targeting unmet medical needs.
- Strategic collaborations with major pharmaceutical companies enhance growth potential.
What Are REGN's Weaknesses?
- Dependence on a limited number of key products for revenue generation.
- Potential regulatory hurdles that could delay product approvals.
- High R&D costs that may impact profitability in the short term.
- Exposure to pricing pressures in the pharmaceutical industry.
What Could Drive REGN Stock Higher?
- Continued expansion of EYLEA's indications through ongoing clinical trials.
- Strong sales growth from Dupixent as it gains traction in new therapeutic areas.
- Potential new product launches from Regeneron's extensive pipeline.
- Strategic collaborations with pharmaceutical partners enhancing research capabilities.
- Regulatory approvals for new therapies in development.
What Are the Key Risks for REGN?
- Regulatory hurdles that could delay product launches.
- Intense competition from other biotechnology firms and generic products.
- Changes in healthcare policy affecting reimbursement rates.
- Market volatility impacting stock performance and investor sentiment.
What Are the Growth Opportunities for REGN?
- Expansion of EYLEA: The global market for age-related macular degeneration treatments is projected to reach $10 billion by 2027. Regeneron aims to expand EYLEA's indications and enhance its market share through ongoing clinical trials and new formulations, potentially increasing revenue significantly over the next five years.
- Dupixent Market Penetration: With the atopic dermatitis market expected to grow to $8 billion by 2025, Dupixent's expansion into additional indications, such as chronic rhinosinusitis, presents a substantial growth opportunity. Regeneron is actively pursuing these new indications, which could drive sales growth and strengthen its market position.
- Rare Disease Pipeline: Regeneron is developing therapies for rare diseases, a segment that is gaining attention due to unmet medical needs. The global rare disease market is anticipated to grow to $300 billion by 2025. Regeneron's focus on innovative treatments in this area could lead to significant revenue contributions in the coming years.
- COVID-19 Treatment Development: The ongoing demand for COVID-19 treatments and potential future pandemics present an opportunity for Regeneron to leverage its REGEN-COV product. Continued development and potential new indications could enhance its revenue streams as global health needs evolve.
- Strategic Collaborations: Regeneron’s partnerships with major pharmaceutical companies, including Sanofi and Bayer, provide access to additional resources and markets. These collaborations are expected to enhance product development and distribution capabilities, driving growth and expanding Regeneron's global footprint.
What Opportunities Does REGN Have?
- Expansion into new therapeutic areas and geographic markets.
- Growing demand for treatments in rare diseases and chronic conditions.
- Potential for new product launches to drive revenue growth.
- Increasing collaborations with biotech firms for innovative therapies.
What Threats Does REGN Face?
- Intense competition from established pharmaceutical companies and new entrants.
- Risks associated with patent expirations and generic competition.
- Regulatory changes that could impact pricing and reimbursement.
- Market volatility affecting investor sentiment and stock performance.
What Are REGN's Competitive Advantages?
- Robust pipeline of innovative products supported by strong R&D capabilities.
- Established reputation and brand recognition in the biotechnology sector.
- Strategic partnerships with leading pharmaceutical companies enhance market access.
- Strong intellectual property protections for proprietary medicines.
- High gross margins due to the premium pricing of specialized therapies.
What Does REGN Do?
Founded in 1988 and headquartered in Tarrytown, New York, Regeneron Pharmaceuticals, Inc. has established itself as a leader in the biotechnology industry by discovering, inventing, developing, manufacturing, and commercializing medicines for a wide range of diseases. The company's flagship products include EYLEA, which is used to treat various eye conditions such as wet age-related macular degeneration and diabetic macular edema, and Dupixent, a breakthrough treatment for atopic dermatitis and asthma. Over the years, Regeneron has expanded its product offerings to include Libtayo for skin cancer, Praluent for cholesterol management, and REGEN-COV for COVID-19, among others. The company has a strong focus on research and development, with a pipeline that includes candidates for eye diseases, allergic and inflammatory conditions, cardiovascular diseases, and cancer. Regeneron has formed strategic collaborations with major pharmaceutical companies such as Sanofi and Bayer, enhancing its ability to innovate and bring new therapies to market. With a workforce of over 15,000 employees, Regeneron is committed to improving patient outcomes through science and innovation, making significant contributions to the healthcare landscape globally.
What Products and Services Does REGN Offer?
- Discover, invent, and develop medicines for various diseases.
- Manufacture and commercialize innovative therapies for eye diseases.
- Provide treatments for asthma and allergic conditions.
- Develop oncology products for various types of cancer.
- Collaborate with other pharmaceutical companies to enhance research capabilities.
- Focus on rare diseases and unmet medical needs through targeted therapies.
How Does REGN Make Money?
- Generate revenue through the sale of proprietary pharmaceutical products.
- Engage in strategic collaborations and licensing agreements with other companies.
- Invest heavily in research and development to innovate new therapies.
- Leverage a strong intellectual property portfolio to protect product innovations.
- Utilize a direct-to-consumer approach for certain products to enhance market reach.
What Industry Does REGN Operate In?
The biotechnology industry is characterized by rapid innovation and a strong focus on research and development, with a global market projected to reach $2.4 trillion by 2028. Regeneron Pharmaceuticals, Inc. operates in a competitive landscape, facing rivals such as Elevance Health Inc., Cigna Corporation, and Zoetis Inc. The increasing demand for advanced therapeutics, particularly in areas like oncology and chronic diseases, positions Regeneron favorably as it continues to expand its product pipeline and leverage its scientific expertise to meet emerging healthcare needs.
Who Are REGN's Key Customers?
- Healthcare providers and hospitals that prescribe and administer therapies.
- Patients suffering from chronic diseases and conditions requiring innovative treatments.
- Pharmaceutical partners engaged in collaborative research and development.
- Government agencies and health organizations for public health initiatives.
- Insurance companies that reimburse for approved therapies.
Company Profile
Regeneron Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Tarrytown, US. The company is led by CEO Leonard S. Schleifer. REGN has traded publicly since 1991.
How Regeneron Pharmaceuticals, Inc. Is Valued
Regeneron Pharmaceuticals, Inc. carries a market capitalization of $67.40B, placing it in the large-cap category. Relative to its peer group, REGN's quantitative score of 90/100 is above the peer average of 74/100.
ROE 14%Key Financial Metrics
Return on equity for Regeneron Pharmaceuticals, Inc. stands at 14.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 10.8%, showing how much profit it generates from its asset base. REGN trades at a trailing price-to-earnings ratio of 14.34, below the Healthcare sector average of ~23x. Its free cash flow yield is 6.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.57 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 6.6%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 5/9Financial Health
Regeneron Pharmaceuticals, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 6.70 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Regeneron Pharmaceuticals, Inc. revenue of about $15.92B for fiscal 2026, with EPS near $46.42. The estimate reflects 20 contributing analysts.
Net sellingInsider Activity
Over the past six months, Regeneron Pharmaceuticals, Inc. insiders filed 30 SEC Form 4 transactions — 30 sales and 0 purchases. On net that is roughly 251 shares disposed (about $188K), a signal worth weighing alongside the fundamentals.
REGN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Regeneron's consistent pipeline advancements suggest potential future revenue streams, fostering long-term growth prospects. Think of it like Amgen's steady performance driven by continuous innovation.
- Positive community sentiment around REGN indicates strong belief in the company's strategic direction and market positioning. It's similar to how positive buzz fueled Tesla's initial rise.
- Recent insider buying activity might signal confidence in the company's future performance, suggesting undervaluation or upcoming positive catalysts. This mirrors situations where execs loaded up on shares before major announcements.
- Regeneron's established partnerships and collaborations enhance its market reach and diversification, reducing reliance on single products. This is like how Johnson & Johnson leverages its diverse portfolio for stability.
Bear Case
- Increased competition in the biopharmaceutical space could erode Regeneron's market share and pricing power. It's a similar threat faced by established players when disruptive technologies emerge.
- Negative community sentiment surrounding potential regulatory hurdles or clinical trial setbacks could dampen investor enthusiasm. Remember the market's reaction to Biogen's Aduhelm controversy.
- Recent insider selling activity may indicate concerns about the company's near-term prospects or strategic direction. It's a red flag that investors often scrutinize, like during the early stages of the 2008 financial crisis when insiders started unloading bank stocks.
- Shifting market perception towards alternative therapies or emerging competitors could negatively impact Regeneron's long-term growth trajectory. The rise of biosimilars posed a similar challenge to many branded drug manufacturers.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · February 2026
From the Earnings Call
“Global DUPIXENT net sales increased 31% on a constant currency basis to $4.9 billion in the quarter.”
— Leonard Schleifer, CEO
“EYLEA HD U.S. net product sales increased 52% year-over-year to $468 million.”
— Leonard Schleifer, CEO
REGN Q1 FY2026 earnings call transcript · 2026-04-29
REGN Latest News
-
Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness
benzinga · Jun 30, 2026
-
Market Chatter: Eli Lilly, Regeneron Among First Companies in FDA PreCheck Pilot Program
MT Newswires · Jun 29, 2026
-
'Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities' - CNBC
benzinga · Jun 29, 2026
-
CDC Raises Its Response Level To Congo Ebola Outbreak To Level 1 Activation, Its Highest Level; Says Risk Of Ebola Spreading In The U.S. Remains Low
benzinga · Jun 26, 2026
REGN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for REGN.
Price Targets
Consensus target: $854.53
REGN MoonshotScore
What does this score mean?
The MoonshotScore rates REGN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness
Market Chatter: Eli Lilly, Regeneron Among First Companies in FDA PreCheck Pilot Program
'Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities' - CNBC
CDC Raises Its Response Level To Congo Ebola Outbreak To Level 1 Activation, Its Highest Level; Says Risk Of Ebola Spreading In The U.S. Remains Low
Latest Regeneron Pharmaceuticals, Inc. Analysis
Related Investment Themes
Leadership: Leonard S. Schleifer
CEO
Leonard S. Schleifer co-founded Regeneron Pharmaceuticals, Inc. in 1988. He holds an M.D. and a Ph.D. from the University of Virginia and has extensive experience in the biotechnology industry. Under his leadership, Regeneron has grown from a small startup into a leading biopharmaceutical company with a strong focus on innovation and research.
Track Record: Leonard has overseen the successful development and commercialization of multiple blockbuster drugs, including EYLEA and Dupixent, significantly contributing to the company's growth and market position.
Common Questions About REGN (Healthcare)
What does Regeneron Pharmaceuticals, Inc. do?
Regeneron Pharmaceuticals, Inc. is a biotechnology company that focuses on discovering, developing, and commercializing innovative medicines for various diseases. Its product portfolio includes treatments for eye diseases, asthma, cancer, and rare diseases, with a strong emphasis on research and development to address unmet medical needs.
What do analysts say about REGN stock?
Analysts generally view REGN stock positively, citing its strong product pipeline and financial performance. Key valuation metrics indicate a favorable position within the biotechnology sector, with a P/E ratio of 14.3 and a profit margin of 29.6%. Growth considerations include the expansion of existing products and the potential for new drug approvals.
What are the main risks for REGN?
Regeneron Pharmaceuticals, Inc. faces several risks, including regulatory hurdles that could impact product approvals and market entry. Additionally, the company is exposed to intense competition from both established pharmaceutical companies and generic alternatives. Changes in healthcare policies may also affect reimbursement rates, posing further challenges to revenue generation.
What are the key factors to evaluate for REGN?
Regeneron Pharmaceuticals, Inc. (REGN) holds an AI score of 90/100 (high). P/E: 14.3x vs the S&P 500's ~20-25x. Analysts target $854.53 (+31%). Not financial advice.
How frequently does REGN data refresh on this page?
REGN prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven REGN's recent stock price performance?
Regeneron Pharmaceuticals, Inc. (REGN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong product portfolio with established market leaders like EYLEA and Dupixent. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider REGN overvalued or undervalued right now?
Regeneron Pharmaceuticals, Inc. (REGN) trades at 14.3x earnings. Analysts target $854.53 (+31%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying REGN?
Before investing in Regeneron Pharmaceuticals, Inc. (REGN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on the latest available information as of May 2026.